MedTrace Logo

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

NCT07423481 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2026-05-13

No results posted yet for this study

Summary

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Conditions

  • Obesity & Overweight

Interventions

OTHER

SEMAFOLLOW questionnaire

If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

Sponsors & Collaborators

Principal Investigators

  • David JACOBI · Nantes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07423481 on ClinicalTrials.gov